Premium Brands Acquires Stampede for $662.5 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
Source: Globenewswire
- Acquisition Agreement: Premium Brands has entered into a definitive agreement to acquire Stampede Culinary Partners for approximately $662.5 million, consisting of $512.5 million in cash and $150 million in common shares, which is expected to significantly enhance its position in the U.S. foodservice market.
- Market Expansion: This acquisition will strengthen Premium Brands' presence in the U.S. foodservice channel, particularly as its current strategies are primarily focused on retail and club store channels, thereby driving overall company growth.
- Production Capability Enhancement: By acquiring Stampede, Premium Brands will gain sous vide cooking capabilities, enhancing its production capacity and is expected to realize cost and growth synergies, further boosting its competitive edge in the market.
- Financial Impact: The acquisition is anticipated to be immediately accretive to adjusted earnings per share, delivering mid-single digit percentage accretion in the first year, with a long-term goal of reducing the total funded debt to adjusted EBITDA ratio to 3.0:1 or lower by 2027.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like PBH with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on PBH
Wall Street analysts forecast PBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBH is 77.00 USD with a low forecast of 71.00 USD and a high forecast of 88.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 63.150
Low
71.00
Averages
77.00
High
88.00
Current: 63.150
Low
71.00
Averages
77.00
High
88.00
About PBH
Prestige Consumer Healthcare Inc. is a consumer healthcare products company. The Company is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
2026 Stock Market and Economic Forecast from Barron’s Roundtable Experts
Market Concerns: Investors are increasingly worried about high valuations, index concentration, circular finance, persistent inflation, and rising government debt.
Geopolitical Developments: A significant geopolitical event occurred on January 3, with the capture of Venezuelan President Nicolás Maduro and his wife by U.S. troops, adding to market uncertainties.
Continue Reading
Prestige Consumer Acquires Pillar5 Pharma to Expand Eye Care Product Line
- E-Commerce Growth: Prestige Consumer reported double-digit consumption growth in e-commerce channels, with online sales representing up to 20% of total sales in fiscal 2025, reflecting the success of its digital strategies and enhancing market competitiveness.
- Acquisition Fuels Growth: The company announced the acquisition of Pillar5 Pharma, expected to close in Q3 of fiscal 2026, which will enhance supply capabilities in the eye care category, securing near-term supply and expanding long-term production capacity, thereby diversifying its product portfolio.
- Stable Solvency: As of the end of Q2 fiscal 2026, Prestige Consumer reported no short-term debt and cash equivalents of $119 million, indicating a robust financial position that helps mitigate risks from economic fluctuations.
- Cost Pressure Challenges: Despite facing approximately $5 million in tariff costs and supply chain disruptions, Prestige Consumer is proactively implementing cost-saving measures and tactical pricing strategies to offset these impacts, ensuring sustained profitability.
Continue Reading